688105.SHG Nanjing Vazyme Biotech Co Ltd
- Market cap
- CNY 12.4B
- P/E
- -
- P/B
- 3.16x
- ROE
- 0.6%
- Dividend yield
- 0.63%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688105.SHG undervalued?
Graham numberThe Graham number of Nanjing Vazyme Biotech Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nanjing Vazyme Biotech Co Ltd fundamental analysis
No fundamental analysis for Nanjing Vazyme Biotech Co Ltd yet.
Nanjing Vazyme Biotech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome …
Full company profileNanjing Vazyme Biotech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nanjing Vazyme Biotech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 112M | 171M | 268M | 1.56B | 1.87B | 3.57B | 1.29B | 1.38B | 1.38B | 1.40B |
| Gross Profit | 90.0M | 140M | 225M | 1.38B | 1.48B | 2.18B | 771M | 940M | -40.5M | 984M |
| Operating Income | 4.52K | 526K | 24.3M | 973M | 771M | 717M | -100M | -61.4M | -40.5M | -4.50M |
| EBITDA | 2.92M | 5.75M | 32.0M | 974M | 800M | 686M | 18.2M | 65.5M | 56.9M | 17.0M |
| Net Income | 3.64M | 1.04M | 25.8M | 822M | 678M | 594M | -71.0M | -18.1M | -17.0M | 21.9M |
| EPS | 0.01 | 0.00 | 0.06 | 2.31 | 1.87 | 1.49 | -0.18 | -0.05 | -0.04 | 0.04 |
| Balance Sheet | ||||||||||
| Total Assets | 188M | 251M | 324M | 1.61B | 4.61B | 6.01B | 5.75B | 5.05B | 5.03B | 4.63B |
| Total Liabilities | 37.6M | 84.7M | 124M | 279M | 480M | 1.39B | 1.72B | 1.11B | 1.24B | 1.03B |
| Shareholders' Equity | 151M | 166M | 200M | 1.33B | 4.13B | 4.61B | 4.03B | 3.95B | 3.80B | 3.61B |
| Cash & Short-term Investments | 88.8M | 83.3M | 93.8M | 1.02B | 3.45B | 3.26B | 3.48B | 2.66B | 805M | 426M |
| Total Debt | 5.54M | 31.2M | 35.7M | 1.15M | 91.2M | 458M | 1.29B | 695M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.86M | -4.00M | 15.2M | 804M | 617M | 735M | 198M | -9.68M | 233M | - |
| Capital Expenditure | 18.8M | 32.1M | 19.9M | 153M | 262M | 963M | 233M | 74.9M | 47.4M | 28.8M |
| Free Cash Flow | -22.7M | -36.1M | -4.68M | 651M | 355M | -228M | -79.9M | -84.6M | 186M | 19.8M |
| Ratios | ||||||||||
| ROE | 2.4% | 0.6% | 12.9% | 61.7% | 16.4% | 12.9% | -1.8% | -0.5% | -0.4% | 0.6% |
| ROA | 1.9% | 0.4% | 8.0% | 51.0% | 14.7% | 9.9% | -1.2% | -0.4% | -0.3% | 0.5% |
| Net Profit Margin | 3.2% | 0.6% | 9.6% | 52.5% | 36.3% | 16.7% | -5.5% | -1.3% | -1.2% | 1.6% |
| Debt to Equity | 0.04x | 0.19x | 0.18x | 0.00x | 0.02x | 0.10x | 0.32x | 0.18x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nanjing Vazyme Biotech Co Ltd dividends
- Dividend yield
- 0.63%
- Forward dividend
- 0.50 CNY
- Payout ratio
- -
- Ex-dividend date
- Jun 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 77.5M | 0.18 | - |
| 2024 | CNY 80.4M | 0.22 | - |
| 2023 | CNY 500M | 1.27 | - |
| 2022 | CNY 120M | 0.30 | 20.2% |
| 2021 | CNY 4.45M | 0.01 | 0.7% |
| 2020 | CNY 1.45M | 0.00 | 0.2% |
| 2019 | CNY 1.25M | 0.00 | 4.9% |
| 2018 | 868K | 0.00 | 83.6% |
| 2017 | 291K | 0.00 | 8.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jun 3, 2026.
Who owns Nanjing Vazyme Biotech Co Ltd
- Insiders 70.37%
- Institutions 9.41%
- Public & others 20.22%
- Shares outstanding 517M
- Free float 172M
Nanjing Vazyme Biotech Co Ltd company profile
- Company name
- Nanjing Vazyme Biotech Co Ltd
- Ticker
- 688105.SHG
- ISIN
- CNE100004ZK3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,002
- Fiscal year end
- December
- Address
- Building D2, Nanjing, China, 210033
- Phone
- 86 25 8577 1179
- Website
- vazyme.com
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and cell and protein research reagents. It also provides NGS library preparation reagents, such as DNA sequencing, RNA sequencing, target capture sequencing, epigenetics, magnetic beads, NGS library quantification, and single-cell sequencing; reagents for biomedicine, including mRNA vaccine/drug key components, drug discovery tools, ELISA kits vaccine evaluation reagents, and semaglutide drug key components; instruments, including automated liquid handling workstation, automatic nucleic acid isolation system, real-time fluorescence quantitative PCR system, fluorescence quantimeter, and micro horizontal centrifuge; lab consumables for equipment comprising robotic pipette tips, robotic microwell plates, robotic deep well plates, and 96-well flat-bottom microplates; and monkeypox solutions. It serves research institutions, high-throughput sequencing service providers, molecular diagnostic reagent manufacturers, pharmaceutical companies, vaccine companies, contract research organizations (CROs), hospitals, and medical institutions. The company was founded in 2012 and is headquartered in Nanjing, China.
Nanjing Vazyme Biotech Co Ltd management
8- Mr. Lin Cao Ph.D.Chairman of the Board & GM · born 1979
- Mr. Wen Xin BiChief Financial Officer · born 1976
- Mr. Guo Yang ZhangEmployee Representative Director · born 1989
- Mr. Lijun Zhang Ph.D.Deputy GM & Director · born 1983
- Ms. Xiao Mei Hu M.B.A.Deputy GM & Director · born 1967
- Mr. Jin HuangBoard Secretary · born 1991
- Mr. Xiaoyu XuDeputy General Manager · born 1984
- Kai ShenAccounting Supervisor